Personalized med labeling may be cure for over-warning syndrome

The advent of personalized medicine should be accompanied by personalized risk messaging on drug labels, thus potentially marking a big step up from current messaging norms. For instance, blogs pharma industry watcher Mark Senak, is it necessary to still put "May make drowsy" "on the bottle even though I've been taking this medication daily for several years?" Several such messages adorned his med containers, "put on the side, around the bottom—anywhere a sticky could be stuck." The showstopper for him was "Discontinue use if pregnant." Senak ponders whether risk advisories that are irrelevant to the patient undermine the credibility of all warnings. Blog

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.